Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Future developments in the pharmacotherapy of lung disease.

Pharmaceutisch weekblad. Scientific edition

Van der Kuy A.
PMID: 1437503
Pharm Weekbl Sci. 1992 Aug 21;14(4):221-3. doi: 10.1007/BF01962543.

Future advances in the pharmacotherapy of lung disease will occur mainly in the treatment of asthma, and will include the development of new long-acting beta 2-agonists, long-acting parasympatholytics, phosphodiesterase inhibitors, corticosteroids with fewer systemic side-effects, and other antiinflammatory drugs....

Cite
Van der Kuy A. Future developments in the pharmacotherapy of lung disease. Pharm Weekbl Sci. 1992;14(4):221-3doi: 10.1007/BF01962543.
Van der Kuy, A. (1992). Future developments in the pharmacotherapy of lung disease. Pharmaceutisch weekblad. Scientific edition, 14(4), 221-3. https://doi.org/10.1007/BF01962543
Van der Kuy, A. "Future developments in the pharmacotherapy of lung disease." Pharmaceutisch weekblad. Scientific edition vol. 14,4 (1992): 221-3. doi: https://doi.org/10.1007/BF01962543
Van der Kuy A. Future developments in the pharmacotherapy of lung disease. Pharm Weekbl Sci. 1992 Aug 21;14(4):221-3. doi: 10.1007/BF01962543. PMID: 1437503.
Copy Download .nbib Format: NLM
Publication bias in the pulmonary/allergy literature: effect of pharmaceutical company sponsorship.

The Israel Medical Association journal : IMAJ

Liss H.
PMID: 16889157
Isr Med Assoc J. 2006 Jul;8(7):451-4.

BACKGROUND: A publication bias exists towards positive results in studies funded by pharmaceutical companies.OBJECTIVES: To determine whether drug studies in the pulmonary/allergy literature also demonstrate a publication bias towards more favorable results when a pharmaceutical company funds the study.METHODS:...

Cite
Liss H. Publication bias in the pulmonary/allergy literature: effect of pharmaceutical company sponsorship. Isr Med Assoc J. 2006;8(7):451-4
Liss, H. (2006). Publication bias in the pulmonary/allergy literature: effect of pharmaceutical company sponsorship. The Israel Medical Association journal : IMAJ, 8(7), 451-4.
Liss, Howard. "Publication bias in the pulmonary/allergy literature: effect of pharmaceutical company sponsorship." The Israel Medical Association journal : IMAJ vol. 8,7 (2006): 451-4.
Liss H. Publication bias in the pulmonary/allergy literature: effect of pharmaceutical company sponsorship. Isr Med Assoc J. 2006 Jul;8(7):451-4. PMID: 16889157.
Copy Download .nbib Format: NLM
[Congress of Pneumology of French Language. Montreal, June 1991].

Revue des maladies respiratoires

[No authors listed]
PMID: 1350362
Rev Mal Respir. 1992;9:R1-105.

No abstract available.

Cite
Congrès de Pneumologie de Langue Francaise. Montréal, Juin 1991. [Congress of Pneumology of French Language. Montreal, June 1991]. Rev Mal Respir. 1992;9:R1-105
(1992). Congrès de Pneumologie de Langue Francaise. Montréal, Juin 1991. [Congress of Pneumology of French Language. Montreal, June 1991]. Revue des maladies respiratoires, 9R1-105.
"Congrès de Pneumologie de Langue Francaise. Montréal, Juin 1991." [Congress of Pneumology of French Language. Montreal, June 1991]. Revue des maladies respiratoires vol. 9 (1992): R1-105.
Congrès de Pneumologie de Langue Francaise. Montréal, Juin 1991. [Congress of Pneumology of French Language. Montreal, June 1991]. Rev Mal Respir. 1992;9:R1-105. French. PMID: 1350362.
Copy Download .nbib Format: NLM
Versatility of liquid crystalline nanoparticles in inflammatory lung diseases.

Nanomedicine (London, England)

Chan Y, Mehta M, Paudel KR, Madheswaran T, Panneerselvam J, Gupta G, Su QP, Hansbro PM, MacLoughlin R, Dua K, Chellappan DK.
PMID: 34184917
Nanomedicine (Lond). 2021 Aug;16(18):1545-1548. doi: 10.2217/nnm-2021-0114. Epub 2021 Jun 29.

No abstract available.

Cite
Chan Y, Mehta M, Paudel KR, et al. Versatility of liquid crystalline nanoparticles in inflammatory lung diseases. Nanomedicine (Lond). 2021;16(18):1545-1548doi: 10.2217/nnm-2021-0114.
Chan, Y., Mehta, M., Paudel, K. R., Madheswaran, T., Panneerselvam, J., Gupta, G., Su, Q. P., Hansbro, P. M., MacLoughlin, R., Dua, K., & Chellappan, D. K. (2021). Versatility of liquid crystalline nanoparticles in inflammatory lung diseases. Nanomedicine (London, England), 16(18), 1545-1548. https://doi.org/10.2217/nnm-2021-0114
Chan, Yinghan, et al. "Versatility of liquid crystalline nanoparticles in inflammatory lung diseases." Nanomedicine (London, England) vol. 16,18 (2021): 1545-1548. doi: https://doi.org/10.2217/nnm-2021-0114
Chan Y, Mehta M, Paudel KR, Madheswaran T, Panneerselvam J, Gupta G, Su QP, Hansbro PM, MacLoughlin R, Dua K, Chellappan DK. Versatility of liquid crystalline nanoparticles in inflammatory lung diseases. Nanomedicine (Lond). 2021 Aug;16(18):1545-1548. doi: 10.2217/nnm-2021-0114. Epub 2021 Jun 29. PMID: 34184917.
Copy Download .nbib Format: NLM
[Differential diagnosis of diffuse interstitial pulmonary diseases].

Klinicheskaia meditsina

Terpigorev SA.
PMID: 21089449
Klin Med (Mosk). 2010;88(5):8-12.

Classification, differential diagnosis and treatment of diffuse interstitial pulmonary diseases are considered. Data on their X-ray (computed tomographic) and morphological manifestations are presented along with analysis of efficiency of pathogenetic (anti-inflammatory and antifibrotic) therapy.

Cite
Terpigorev SA. [Differential diagnosis of diffuse interstitial pulmonary diseases]. Klin Med (Mosk). 2010;88(5):8-12
Terpigorev, S. A. (2010). [Differential diagnosis of diffuse interstitial pulmonary diseases]. Klinicheskaia meditsina, 88(5), 8-12.
Terpigorev, S A. "[Differential diagnosis of diffuse interstitial pulmonary diseases]." Klinicheskaia meditsina vol. 88,5 (2010): 8-12.
Terpigorev SA. [Differential diagnosis of diffuse interstitial pulmonary diseases]. Klin Med (Mosk). 2010;88(5):8-12. Russian. PMID: 21089449.
Copy Download .nbib Format: NLM
Protein Misfolding and Endoplasmic Reticulum Stress in Chronic Lung Disease: Will Cell-Specific Targeting Be the Key to the Cure?.

Chest

Naiel S, Tat V, Padwal M, Vierhout M, Mekhael O, Yousof T, Ayoub A, Abed S, Dvorkin-Gheva A, Ask K.
PMID: 31778676
Chest. 2020 May;157(5):1207-1220. doi: 10.1016/j.chest.2019.11.009. Epub 2019 Nov 26.

Chronic lung disease accounts for a significant global burden with respect to death, disability, and health-care costs. Due to the heterogeneous nature and limited treatment options for these diseases, it is imperative that the cellular and molecular mechanisms underlying...

Cite
Naiel S, Tat V, Padwal M, et al. Protein Misfolding and Endoplasmic Reticulum Stress in Chronic Lung Disease: Will Cell-Specific Targeting Be the Key to the Cure?. Chest. 2019;157(5):1207-1220doi: 10.1016/j.chest.2019.11.009.
Naiel, S., Tat, V., Padwal, M., Vierhout, M., Mekhael, O., Yousof, T., Ayoub, A., Abed, S., Dvorkin-Gheva, A., & Ask, K. (2020). Protein Misfolding and Endoplasmic Reticulum Stress in Chronic Lung Disease: Will Cell-Specific Targeting Be the Key to the Cure?. Chest, 157(5), 1207-1220. https://doi.org/10.1016/j.chest.2019.11.009
Naiel, Safaa, et al. "Protein Misfolding and Endoplasmic Reticulum Stress in Chronic Lung Disease: Will Cell-Specific Targeting Be the Key to the Cure?." Chest vol. 157,5 (2020): 1207-1220. doi: https://doi.org/10.1016/j.chest.2019.11.009
Naiel S, Tat V, Padwal M, Vierhout M, Mekhael O, Yousof T, Ayoub A, Abed S, Dvorkin-Gheva A, Ask K. Protein Misfolding and Endoplasmic Reticulum Stress in Chronic Lung Disease: Will Cell-Specific Targeting Be the Key to the Cure?. Chest. 2020 May;157(5):1207-1220. doi: 10.1016/j.chest.2019.11.009. Epub 2019 Nov 26. PMID: 31778676.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries